CHMP positive opinions for AstraZeneca, Merck KGaA, Roche, Alcon and Merck-Serono
This article was originally published in Scrip
Executive Summary
The November meeting of the Committee for Medicinal Products for Human Use (CHMP) only gave a positive opinion to one new medicine, AstraZeneca’s anticancer, Caprelsa (vandetanib), but recommended positive indications extensions for four other drugs: Merck KGaA’s Erbitux (cetuximab) in metastatic colorectal cancer; Roche’s herceptin (trastuzumab) in breast cancer; Alcon/Novartis’s Nevanac (nepafenac) in reducing the risk of macular oedema following cataract srgery; and Merck-Serono’s Rebif (interferon beta-1a) in early stages of multiple sclerosis.